Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

New strategy for breast cancer treatment: Neoribocic inhibits tumor proliferation through cell cycle blockade

ABSTRACT: New strategy for breast cancer treatment: Neoribocic inhibits tumor proliferation through cell cycle blockade

PROVIDER: PRJNA1249459 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR33082296_1.fastq.gz	Fastqsanger.gz
	SRR33082296_2.fastq.gz	Fastqsanger.gz
	SRR33082297_1.fastq.gz	Fastqsanger.gz
	SRR33082297_2.fastq.gz	Fastqsanger.gz
	SRR33082298_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

New strategy for breast cancer treatment: Neoribocic inhibits tumor proliferation through cell cycle blockade

Project description:As one of the most common malignant tumors in the world, breast cancer is still a major challenge to human health despite the continuous improvement of treatment methods. Therefore, it is of great clinical significance to develop new anti-breast cancer drugs to improve the therapeutic effect. As a CDK4/6 inhibitor, Ribociclib has shown potential in breast cancer treatment. Based on this, we designed and synthesized a new type of ribocyclib derivative Neoribocic, and deeply studied its role mechanism in breast cancer. Research results show that Neoribocic can significantly inhibit the proliferation, migration and invasion ability of breast cancer cells in in vitro experiments, and show excellent anti-tumor activity. By analyzing MDA-MB-231 cells treated with Neoribocic through RNA sequencing (RNA-Seq), we found that Neoribocic may block the progression of breast cancer cells in the G2/M stage by activating the p53 signaling pathway, thus exerting their anti-tumor effect. . In addition, in vivo experiments further confirm that Neoribocic can not only effectively inhibit tumor growth, but also significantly inhibit the angiogenesis in the chicken embryonic cyst membrane, suggesting that it may have an anti-angiogenesis effect.

2025-04-11 | GSE294436 | GEO

Esomeprazole Inhibits Proliferation of Scleroderma Fibroblasts via Cell Cycle Regulation

Project description:Esomeprazole Inhibits Proliferation of Scleroderma Fibroblasts via Cell Cycle Regulation

| PRJNA1390281 | ENA

CD36 deficiency inhibits proliferation by cell cycle control in skeletal muscle cells

Project description:CD36 deficiency inhibits proliferation by cell cycle control in skeletal muscle cells

| PRJNA841963 | ENA

ATOH8 inhibits cell proliferation through transcriptional regulating cell cycle related genes [RNA-seq]

Project description:ATOH8 inhibits cell proliferation through transcriptional regulating cell cycle related genes [RNA-seq]

| PRJNA785650 | ENA

Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone

Project description:Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone

| PRJNA989249 | ENA

BMH-21 inhibits RNA polymerase I transcription cycle and rDNA occupancy

Project description:BMH-21 inhibits RNA polymerase I transcription cycle and rDNA occupancy

| PRJNA732709 | ENA

Esomeprazole Inhibits Proliferation of Scleroderma Fibroblasts via Cell Cycle Regulation

Project description:Scleroderma is a complex autoimmune disease characterized by abnormal fibroblast proliferation and excessive collagen deposits in the skin and internal organs. We previously showed that esomeprazole, an FDA-approved drug for gastric disorders, may prevent dermal fibrosis. Here, we demonstrate that esomeprazole exerts anti-proliferative effects on scleroderma fibroblasts by interfering with cell cycle regulation. To test this, we evaluated the antiproliferative effect of esomeprazole and the underlying molecular mechanisms using primary fibroblasts derived from patients with scleroderma. BrdU incorporation, flow cytometry, immunofluorescence, Western blot analysis, RNA sequencing, and functional enrichment analysis all showed a decrease in fibroblast proliferation. In addition, esomeprazole inhibited the proliferation of scleroderma fibroblasts in a dose-dependent manner, as measured by the Ki-67 marker. Intriguingly, esomeprazole arrested fibroblasts in the G1 phase of the cell cycle, resulting in a reduction of cells in the S phase. Expression of p21, a known inhibitor of cyclin-dependent kinases (CDKs), was elevated, while CDK1 and CDK2 levels decreased following esomeprazole treatment. These data provide important insights into how esomeprazole regulates fibroblast proliferation in scleroderma and suggest that it may represent a potential therapeutic intervention for scleroderma.

2025-12-17 | GSE314222 | GEO

Combined blockade of B7-H3 and CD47 immune checkpoints is a new therapeutic strategy for β-catenin driven melanomas

Project description:Combined blockade of B7-H3 and CD47 immune checkpoints is a new therapeutic strategy for β-catenin driven melanomas

| PRJNA675821 | ENA

Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infection.

Project description:Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infection.

| PRJNA1031548 | ENA

life strategy

Project description:life strategy

| PRJEB48189 | ENA